BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/10/2014 5:06:00 PM | Browse: 1079 | Download: 941
Publication Name World Journal of Hepatology
Manuscript ID 3957
Country/Territory Canada
Received
2013-06-04 19:32
Peer-Review Started
2013-06-05 09:44
To Make the First Decision
2013-06-24 10:31
Return for Revision
2013-07-17 15:48
Revised
Second Decision
2013-10-16 11:14
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-10-16 12:04
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-10-23 18:33
Publish the Manuscript Online
2013-10-25 08:47
ISSN 1948-5182 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Case Report
Article Title Severe cholestasis due to adalimumab in a Crohn’s disease patient
Manuscript Source Invited Manuscript
All Author List Edward Kim, Brian Bressler, David F Schaeffer and Eric M Yoshida
Funding Agency and Grant Number
Corresponding Author Eric M Yoshida, MD, Professor of Medicine, Head, Division of Gastroenterology, University of British Columbia, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada. eric.yoshida.@vch.ca
Key Words Crohn’s disease; Cholestasis; Adalimumab; Anti-tumor necrosis factor agents; Drug-induced liver injury
Core Tip Anti-tumor necrosis factor agents are commonly used in the treatment of inflammatory bowel disease and other inflammatory conditions. Drug-induced injury to the liver induced by the agents includes autoimmune hepatitis, direct hepatocellular necrosis and cholestasis. Our patient, a 39-year-old female with Crohn’s disease, developed severe jaundice after initiation of adalimumab. We present the first report of adalimumab-associated severe cholestatic injury and the first histopathologic examination of this adverse drug effect. Clinicians need to be aware of this potential severe drug-induced liver injury when prescribing this commonly used biologic medication.
Publish Date 2013-10-25 08:47
Citation Kim E, Bressler B, Schaeffer DF, Yoshida EM. Severe cholestasis due to adalimumab in a Crohn’s disease patient. World J Hepatol 2013; 5(10): 592-595
URL http://www.wjgnet.com/1948-5182/full/v5/i10/592.htm
DOI http://dx.doi.org/10.4254/wjh.v5.i10.592
Full Article (PDF) WJH-5-592.pdf
Manuscript File 3957-Review.doc
Answering Reviewers 3957-Answering reviewers.pdf
Copyright License Agreement 3957-Copyright assignment.pdf
Peer-review Report 3957-Peer review(s).pdf
Scientific Editor Work List 3957-Scientific editor work list.doc